Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.
Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.
复制标题
血清 RANTES 水平影响慢性丙型肝炎对聚乙二醇干扰素和利巴韦林治疗的反应。
DOI：
10.1111/hepr.12032
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Enomoto N
中科院分区：
文献类型：
--
作者：
Komase K;Maekawa S;Miura M;Sueki R;Kadokura M;Shindo H;Shindo K;Amemiya F;Nakayama Y;Inoue T;Sakamoto M;Yamashita A;Moriishi K;Enomoto N
目的预测基因 1b 型慢性丙型肝炎对聚乙二醇化干扰素 (PEG IFN) 联合利巴韦林 (RBV) 治疗的疗效尚不确定。方法本研究通过夹心酶联免疫分析 (ELISA) 和微珠阵列对 96 名患者进行了 36 种治疗前血清趋化因子/细胞因子水平与 PEG IFN/RBV 治疗效果之间的相关性研究。对随机选择的 31 名患者进行夹心 ELISA 半定量分析，发现持续病毒学应答 (SVR) 组血清中激活正常 T 细胞表达和分泌调节 (RANTES) 水平显着高于非 SVR 组 (P= 0.048)。使用珠阵列对所有 96 名患者进行的精确 RANTES 测量证实了这种相关性 (P= 0.002)。然而，遗传RANTES单倍型与血清水平没有显着相关。通过多变量分析提取血清RANTES水平（比值比 = 4.09，95%置信区间 = 1.02–16.5，P= 0.048）作为促进SVR的自变量。结论血清RANTES水平是影响慢性丙型肝炎PEG IFN/RBV治疗病毒学应答的重要决定因素。
AimPrediction of treatment responses to pegylated interferon (PEG IFN) plus ribavirin (RBV) therapy is uncertain for genotype 1b chronic hepatitis C.MethodsIn this study, 96 patients were investigated for the correlation between 36 pretreatment serum chemokine/cytokine levels and PEG IFN/RBV treatment efficacy by a sandwich enzyme‐linked immunoassay (ELISA) and a bead array.ResultsFirst, chemokines/cytokines were measured semiquantitatively by sandwich ELISA in 31 randomly‐selected patients and the serum regulated on activation normal T‐cell expressed and secreted (RANTES) level was found to be significantly higher in the sustained virological response (SVR) group than the non‐SVR group (P= 0.048). Precise RANTES measurement in all 96 patients using a bead array confirmed this correlation (P= 0.002). However, the genetic RANTES haplotype was not significantly related to the serum level. The serum RANTES level was extracted by multivariate analysis (odds ratio = 4.09, 95% confidence interval = 1.02–16.5,P= 0.048) as an independent variable contributing to SVR.ConclusionThe serum RANTES level is an important determinant influencing the virological response to PEG IFN/RBV therapy in chronic hepatitis C.